Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products … Read more
Hansoh Pharmaceutical Group Company Limited (HNSPF) - Total Liabilities
Latest total liabilities as of June 2025: $3.97 Billion USD
Based on the latest financial reports, Hansoh Pharmaceutical Group Company Limited (HNSPF) has total liabilities worth $3.97 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hansoh Pharmaceutical Group Company Limited - Total Liabilities Trend (2020–2024)
This chart illustrates how Hansoh Pharmaceutical Group Company Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hansoh Pharmaceutical Group Company Limited Competitors by Total Liabilities
The table below lists competitors of Hansoh Pharmaceutical Group Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kingsemi Co Ltd
SHG:688037
|
China | CN¥2.99 Billion |
|
Itissalat Al-Maghrib (IAM) S.A
PINK:MAOTF
|
USA | $51.67 Billion |
|
Freddie Mac
LSE:0IKZ
|
UK | $2.91 Trillion |
|
Exponent Inc
NASDAQ:EXPO
|
USA | $387.18 Million |
|
S-Oil Corp
KO:010950
|
Korea | ₩16.34 Trillion |
|
Guangzhou Great Power Energy&Technology Co Ltd
SHE:300438
|
China | CN¥14.96 Billion |
|
Centerra Gold Inc
NYSE:CGAU
|
USA | $750.52 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Hansoh Pharmaceutical Group Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hansoh Pharmaceutical Group Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hansoh Pharmaceutical Group Company Limited (2020–2024)
The table below shows the annual total liabilities of Hansoh Pharmaceutical Group Company Limited from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.98 Billion | -58.89% |
| 2023-12-31 | $7.24 Billion | -1.50% |
| 2022-12-31 | $7.35 Billion | +3.14% |
| 2021-12-31 | $7.13 Billion | +144.52% |
| 2020-12-31 | $2.92 Billion | -- |